SLC3A1 and neoplasm: A mutation in either gene confers upon the mutant enzyme a neo-function, resulting in the production of the onco-metabolite D-2-hydroxyglutarate (D2H) which through genome-wide histone and DNA modification results in a hypermethylated phenotype.[17–19] Paradoxically, after transformation, D2H may actually restrain tumour growth.